Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

NCT01369498 | Completed Phase 2 Results FDA Drug

• 1 other identifier: AB0024-102
• Study Type: interventional
• Target: 54
• Locations: 1 country
• Sites: 7

Brief Summary

This study is to evaluate the efficacy and safety of simtuzumab (GS-6624) on bone marrow fibrosis either alone or in combination with ruxolitinib in participants with primary myelofibrosis (PMF) and post polycythemia vera or post essential thrombocythemia myelofibrosis (ET/PV MF). The study is designed as a two-stage trial. In the stage 1, participants will be randomized into two cohorts to receive either 200 or 700 mg of study drug. In the stage 2, participants on ruxolitinib will be randomized to receive either 200 or 700 mg of study drug.

Conditions

Myelofibrosis

Keywords

Hematology; Myelofibrosis; Thrombocythemia Myelofibrosis; Bone Marrow Diseases; Hematologic Diseases; Blood Diseases; Leukemia; Blood Disorders

Outcome Measures

Primary Outcomes (1)

• Rate of Clinical Response as Defined by the Percentage of Participants With Reduction at Week 24 From Baseline in the Bone Marrow Fibrosis Score

  Overall response for the study drug is defined by the reduction in bone marrow fibrosis score which is on a scale of 0-3 where 0 indicates the scattered linear reticulin with no fiber intersections representing normal marrow and 3 indicates dense increase in reticulin fibrosis with fiber intersections, often with osteosclerosis. Reduction from baseline of score indicates improvement in clinical condition.

  Baseline; Week 24

Secondary Outcomes (5)

• Rate of Clinical Response as Defined by the Percentage of Participants With Improvement in Hemoglobin, Platelet, or Absolute Neutrophil Count (ANC)

  Baseline; Weeks 12, 24 and any time post baseline (enrollment up to 94 weeks)

• Percentage of Participants With Adverse Events (AEs)

  First dose date up to the last dose date (maximum: 94 weeks) plus 28 days

• Change From Baseline in Myelofibrosis Symptoms Assessment Score

  Baseline; Days 43 and 85 of Cycles 1-7 (cycle=12 weeks)

• Change From Baseline in Cytokine Levels

  Baseline; Week 24

• Percentage of Participants With Anti-Simtuzumab Antibody Formation

  Baseline; Day 85 of Cycles 1 to 5 (cycle=12 weeks)

Study Arms (4)

Simtuzumab 200 mg

EXPERIMENTAL

Participants in Stage 1 of study will receive simtuzumab 200 mg for up to 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.

Drug: Simtuzumab

Simtuzumab 700 mg

EXPERIMENTAL

Participants in Stage 1 of study will receive simtuzumab 700 mg for up to 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.

Drug: Simtuzumab

Simtuzumab 200 mg+Ruxolitinib

EXPERIMENTAL

In Stage 2, participants on stable doses of ruxolitinib will receive simtuzumab 200 mg for at least 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.

Drug: Simtuzumab; Drug: Ruxolitinib

Simtuzumab 700 mg+Ruxolitinib

EXPERIMENTAL

In Stage 2, participants on stable doses of ruxolitinib will receive simtuzumab 700 mg for at least 24 weeks. Treatment could be continued if there is evidence of clinical benefit as judged by the treating physician.

Drug: Simtuzumab; Drug: Ruxolitinib

Interventions

Simtuzumab DRUG

Simtuzumab administered intravenously over approximately 30 minutes every 2 weeks

Also known as: GS-6624, AB0024

Simtuzumab 200 mg; Simtuzumab 200 mg+Ruxolitinib; Simtuzumab 700 mg; Simtuzumab 700 mg+Ruxolitinib

Ruxolitinib DRUG

In Stage 2, participants will be on a stable dose of ruxolitinib

Simtuzumab 200 mg+Ruxolitinib; Simtuzumab 700 mg+Ruxolitinib

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Must be diagnosed with PMF or post ET/PV MF with intermediate-1, intermediate-2 or high risk disease according to the international working group (IWG) prognostic scoring system, or if with low risk disease then with symptomatic splenomegaly that is ≥ 10 cm below left costal margin by physical exam.
• Must have adequate organ function as demonstrated by the following:
• Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≤ 2.5x upper limit of normal (ULN), or ≤ 4x ULN (if upon judgment of the treating physician, it is believed to be due to extramedullary hematopoiesis \[EMH\] related to MF);
• Direct bilirubin ≤ 1.5 x ULN; or ≤ 2x ULN (if upon judgment of the treating physician, it is believed to be due to extramedullary hematopoiesis \[EMH\] related to MF);
• Serum creatinine ≤ 2.5 mg/dL.
• In Stage 2, participants must be on ruxolitinib for at least 8 weeks and on a stable dose for at least 4 weeks.
• Eastern cooperative oncology group (ECOG) performance status (PS) ≤ 2
• Treatment-related toxicities from prior therapies must have resolved to Grade ≤ 1
• Women of childbearing potential and men must agree to using one medically approved (ie, mechanical or pharmacological) contraceptive measure and have their partners agree to an additional barrier method of contraception for the duration of the study and for 90 days after the last administration of study drug. Definition of female of child bearing potential and a list of acceptable contraceptive methods for this study applies per protocol.

You may not qualify if:

• Any serious medical condition or psychiatric illness that would prevent, (as judged by the treating physician) the participant from signing the informed consent form or any condition, including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
• Pregnant or lactating.
• Known history of human immunodeficiency virus (HIV), hepatitis C, or hepatitis B.
• History or presence of any form of cancer within the 3 years prior to enrollment, with the exception of excised basal cell or squamous cell carcinoma of the skin, or cervical carcinoma in situ or breast carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis.
• Participation in an investigational drug or device trial within 2 weeks prior to study Day 1 or within 5 times the half-life of the investigational agent in the other clinical study, if known.
• Use of any cytotoxic chemotherapeutic agents (eg, hydroxyurea), corticosteroids (prednisone ≤ 10 mg/day or corticosteroid equivalent is allowed), or immune modulators (eg, thalidomide) within 2 weeks and interferon use within 4 weeks prior to study Day 1.
• Symptomatic congestive heart failure (New York Heart Association Classification \> Class II), unstable angina, or unstable cardiac arrhythmia requiring medication.
• History of surgery within 2 weeks prior to enrollment or anticipated surgery during the study period.
• Any other condition that might reduce the chance of obtaining data required by the protocol or that might compromise the ability to give truly informed consent.

Sponsors & Collaborators

• Gilead Sciences: lead

Study Sites (7)

Mayo Clinic

Scottsdale, Arizona, 85259, United States

Location

Stanford University Medical center

Stanford, California, 94305, United States

Location

Washington University in St. Louis

St Louis, Missouri, 63110, United States

Location

Oncology Hematology Care Clinical Trials

Cincinnati, Ohio, United States

Location

Cleveland Clinic

Cleveland, Ohio, United States

Location

Tennessee Oncology

Nashville, Tennessee, United States

Location

MD Anderson Cancer Center

Houston, Texas, 77030, United States

Location

MeSH Terms

Conditions

Primary Myelofibrosis; Bone Marrow Diseases; Hematologic Diseases; Leukemia

Interventions

simtuzumab; ruxolitinib

Condition Hierarchy (Ancestors)

Myeloproliferative Disorders; Hemic and Lymphatic Diseases; Neoplasms by Histologic Type; Neoplasms

Results Point of Contact

• Title: Gilead Clinical Study Information Center
• Organization: Gilead Sciences

GileadClinicalTrials@gilead.com

1-833-445-3230 (GILEAD-0)

Study Officials

• Gilead Study Director

  Gilead Sciences

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 6, 2011
• First Posted: June 9, 2011
• Study Start: June 30, 2011
• Primary Completion: June 5, 2014
• Study Completion: September 24, 2014
• Last Updated: July 1, 2020
• Results First Posted: July 1, 2020

Record last verified: 2020-06

Data Sharing

• IPD Sharing: Will not share

Locations

US (7)